Long noncoding RNA TANCR promotes γδ T cells activation by regulating TRAIL expression in cis

Chuan Yang1, Ting Feng1, Fang Lin1, Tinxiang Gong2, Shuo Yang1, Yuhong Tao3 and Hong Li1*

Abstract

Background: γδ T cells are an important subset of T lymphocytes that play important roles in innate and adaptive immunity via the secretion of various cytokines. Previous studies have found that long noncoding RNAs (lncRNAs) are critical regulators that contribute to the development of immune cells. However, the functions of lncRNAs in the γδ T cells remains poorly studied.

Results: Here, we identified the novel function of lncRNA NONHSAT196558.1 in isopentenyl pyrophosphate (IPP)-activated and -expanded γδ T cells using RNA-seq. As it functioned as an activating noncoding RNA of tumor necrosis factor related apoptosis-inducing ligand (TRAIL), an important cytotoxic cytokine that expressed by γδ T cells in responding to various infectious agents, we named this lncRNA as TANCR. Secondly, the expression of TANCR was found to be positively correlated with TRAIL expression in IPP activated γδ T cells. In addition, TANCR was confirmed to localized both in nucleus and cytoplasm. Finally, a loss-of-function was conducted by using siRNA/ASO or CRISPR/ Cas9 system to knockdown or knockout TANCR, and confirmed that silencing of TANCR inhibits TRAIL expression in several kinds of cells, including HEK293T cells, Jurkat cells, and primary γδ T cells.

Conclusion: These evidences demonstrate that TANCR play important roles in γδ T cell activation. Furthermore, TANCR may be involved in the cytotoxicity of γδ T cells. This study aims to further our understanding of the molecular mechanisms underlying lncRNA-mediated immune responses.

Keywords: LncRNA, γδ T cells, TRAIL, Immune cells, TANCR

Background

γδ T cells are a subset of T lymphocytes that are classified as CD3 and T cell receptor (TCR) γδ double positive [1, 2]. γδ T cells occupy 5–10 percentage of peripheral T cells, while γδ T cells can be as high as 50% of total CD3+ T cells in some mucosal tissues [3, 4]. γδ T cells play critical roles in defending against various infections. On one hand, γδ T cells lyse target cells via granzyme-perforin secretion [5, 6]. On the other, they also trigger apoptosis of target cell through factor associated suicide (Fas)-Fas ligand (FasL), interferon-γ (IFN-γ) and TRAIL. Furthermore, γδ T cells can recruit other immune cells like dendritic cells, granulocytes, and langerhans cells to increase their anti-infection ability [7–9]. γδ T cells can differentiate into antigen presenting cells (APCs) and present antigens to αβ T cells [10]. In addition, γδ T cells modulate an immune response by regulating Foxp3(+) T reg cells proliferation and secreting interleukin 10 (IL-10) and transforming growth factor β (TGF-β) [11]. The functions of γδ T cells are showed in Fig. 1 (edited according to reference [12]).
It is well known that the majority of the genome transcribes noncoding genes and the functions of various noncoding genes are unknown [13]. Micro-RNAs are a well-known noncoding RNA type that regulates gene expression by binding to the 3′ untranslated region of a target gene [14]. LncRNA is transcript that is longer than 200 nucleotides [13]. LncRNAs modulate gene expression via binding to proteins or interacting with DNA/RNA directly [15–17]. LncRNA mediation of cis regulation involves neighboring genes that transcribed from the same allele. While when lncRNA exerts its influence on a distantly located genes, lncRNA act in trans [18]. Previous studies have showed the evidence that lncRNA regulate various genes in the immune system. For example, the lncRNA NeST controls the expression of the interferon-γ locus in response to bacterial infection [19]. LncRNA lnc-DC regulates the differentiation of dendritic cell via binding to signal transducer and activator of transcription 3 [20]. Long intergenic ncRNA EPS acts as an inhibitor in the inflammatory response in macrophages [21]. Taken together, these evidences strongly indicate that lncRNAs act as critical regulators in the immune system. However, there are few studies about lncRNA regulation in γδ T cells. Hence, exploring the lncRNA regulation network in γδ T cells may help us better understand the function of lncRNA in γδ T cell biology.

IPP is a mevalonate pathway product that can selectively activate and expand human γδ T cells [22–24]. In this study, γδ T cells were activated by IPP, and then we investigated the differentially expressed genes including lncRNAs and mRNAs in the activated of γδ T cells compared with fresh γδ T cells using RNA-seq. Bioinformatic analysis was performed to predict lncRNA–mRNA pairs that regulated in cis, we found that the lncRNA NONHSAT196558.1 (named as TANCR [25]) expressed much higher in IPP-activated γδ T cells, and positively correlated with tumor necrosis factor related apoptosis-inducing ligand (TRAIL, also known as TNFSF10) expression. Using siRNA/ASO or CRISPR/Cas9 system to knockdown or knockout TANCR confirmed that silencing of TANCR inhibits TRAIL expression. The current results demonstrate that TANCR positively regulates TRAIL expression in the activation of γδ T cells, which provide epigenetic mechanisms in understanding lncRNAs in γδ T cells.

**Results**

**Expansion of γδ T cells**

To obtain activated γδ T cells, IPP was used to activate γδ T cell. Freshly isolated (peripheral blood mononuclear cells) PBMCs were obtained from healthy adult donors. After three weeks of culture in the presence of IL-2 and IPP, the percentage of γδ T cells within CD3 cells increased to 84.3% (Fig. 2b). To determine whether γδ T cells were activated by IPP, we examined cell surface markers (CD69, NKG2D, and TRAIL) in fresh and IPP expanded γδ T cells. As shown in Fig. 2, fresh γδ T cells expressed low levels of CD69, NKG2D, and TRAIL. In
contrast, IPP expanded γδ T cells expressed much higher levels of CD69, NKG2D, and TRAIL compared with fresh γδ T cells (Fig. 2a, b). Then fresh and IPP expanded γδ T cells were purified with MACS, respectively. RNA was extracted and sent for RNA-seq.

Characteristics of differentially expressed lncRNAs and mRNAs in IPP-expanded γδ T cells

In order to explore the lncRNA–mRNA pairs that regulated in cis in γδ T cell activation, a PossionDis assay was used to analyze the differentially expressed mRNA and lncRNA. In total, 18,183 mRNAs and 5378 lncRNAs were found to be differentially expressed (fold change > 2, p-value < 0.05). A volcano plot was used to display the differentially expressed mRNAs and lncRNAs (Fig. 3a, b). The results showed that the expression of mRNA and lncRNA in IPP-expanded γδ T cells was significantly different from the fresh γδ T cells, which indicates that there might be lncRNA-mRNA interactions in the differentially expressed genes. LncRNA-mRNA interactions are an important regulatory mechanism of lncRNAs. We then analyzed the cis-regulation of differentially expressed genes based on the co-localization and co-expression of the lncRNAs and mRNAs. The top 15 upregulated and downregulated lncRNAs and target mRNAs are shown in Table 1.

To further study the function of differentially expressed lncRNA-targeted mRNAs in the activation of γδ T cells, Go and KEGG analysis were performed. Go analysis revealed that the most frequent terms were cellular process in biological process, cell in cellular component, and binding in molecular function (Fig. 3c). The KEGG results showed the 20 top enriched pathways (Fig. 3d). T cell receptor signaling pathway, Th17 cell differentiation, and Th1 and Th2 cell differentiation are included in the 20 top enriched pathways, which indicates that the differentially expressed lncRNA-targeted mRNAs may be involved in T cell activation. Genes including mRNA and lncRNA that were differentially expressed between IPP-expanded and fresh γδ T cells were then analyzed by a hierarchical cluster (fold change), which demonstrates that the genes were distinguishable between the two groups (Fig. 4a, b).

TANCR is expressed highly in the nucleus and is positively correlated with TRAIL expression

To validate the sequencing results, eight genes were selected to validate using reverse transcription polymerase chain reaction (RT-PCR), including mRNA and lncRNA (caspase3, intercellular cell adhesion molecule-1 (ICAM-1), programed death-1 (PD-1), natural killer cell receptor G2A (NKG2A), TRAIL, TANCR, NONHSAT037278.2, and LTCONS_00091384). The RT-PCR results were similar to those observed in sequencing results (Fig. 5a, b). TRAIL is considered as important cytokine that mediates γδ T cell cytotoxicity. In addition, bioinformatic analysis also showed that lncRNA TANCR may regulate TRAIL expression in cis.
In order to test whether TANCR expression correlate with TRAIL expression, we treated PBMCs isolated from seven donors with IPP and detected the expression of TRAIL and TANCR in purified γδ T cells. qRT-PCR results showed that both TRAIL mRNA and TANCR were increased in IPP-expanded γδ T cells (Fig. 5c, d). The expression of TRAIL also correlated with TANCR expression (Fig. 5e). These results indicated that TANCR might regulate TRAIL mRNA expression in cis. In order to know whether TANCR specifically expressed in γδ T cells, we then performed qRT-PCR in six different cell types including Jurkat cell line, K562 cell line, A549 cell line, L-02 cell line, HEK293T cell line, and γδ T cells. Our results showed that TANCR is more highly expressed in γδ T cells than the other five cell types (Fig. 5f), suggesting that TANCR might be specifically expressed in γδ T cells and regulate TRAIL expression.

TANCR is a transcript that located in the downstream of TRAIL mRNA in Chromosome 3 (Fig. 6a). To clarify the localization of TANCR, nuclear RNA and cytoplasmic RNA was extracted from HEK293T cell line and Jurkat cell line. GAPDH and U6 were used as
cytoplasmic and nuclear control, respectively. qRT-PCR results showed that TANCR expressed both in the cytoplasm and nucleus, while TANCR is predominantly expressed in the cytoplasm and partially expressed in the nucleus (Fig. 6b, c).

Overexpression/knockdown of TANCR in HEK293T cells affects TRAIL expression
To confirm whether TANCR affects TRAIL expression, we constructed pcDNA3.1-TANCR vector and transfected it into HEK293T cells. The RT-PCR and Western blot results showed that TRAIL expression was increased both in mRNA and protein level in TANCR overexpressed HEK293T cell (Fig. 7a, b). Small interfering RNAs (siRNA) and antisense oligonucleotides (ASO) were then transfected into HEK293T cells to knockdown TANCR expression in both cytoplasm and nucleus based on the localization of TANCR explored above. The RT-PCR results showed that siRNA and ASO can reduce the expression of TANCR (Fig. 8a). With the downregulation of TANCR, both mRNA and protein expression of TRAIL was decreased (Fig. 8b, c).

Loss of TANCR abolishes TRAIL expression in Jurkat cells and primary γδ T cell
To further confirm the regulation between and TANCR and TRAIL, CRISPR/Cas 9 system was used to knock out TANCR expression in Jurkat cells and primary γδ T cells. CRISPR/Cas 9 vector with GFP was first transduced into Jurkat cells, and the cells expressed high level of Cas 9 (Fig. 8d). Two guide RNAs were then transduced into Jurkat cells with lentivirus system. The results showed that both two guide RNAs could effectively reduce the expression of TANCR in Jurkat cells (Fig. 8e). And a correlation of a reduced expression of TRAIL mRNA and

Table 1 Top 15 up and down regulated lncRNA and target mRNA

| LncRNA ID     | LncRNA location | Target mRNA | Control FPKM | Exp FPKM | FC | Up/down | p value      |
|---------------|-----------------|-------------|---------------|----------|----|---------|--------------|
| NONHSAT121988.2 | cis_mRNA_overlap | NM_001145306 | 0.01         | 7.28     | 728 | Up      | 3.77E–70    |
| NONHSAT137540.2 | cis_mRNA_overlap | NR_003255   | 0.02         | 5.32     | 266 | Up      | 1.23E–294   |
| NONHSAT152541.1 | cis_mRNA_overlap | NM_003762   | 0.01         | 2.06     | 206 | Up      | 6.51E–18    |
| NONHSAT137555.2 | cis_mRNA_overlap | NR_003255   | 0.02         | 3.96     | 198 | Up      | 4.72E–99    |
| NONHSAT182712.1 | cis_mRNA_overlap | NM_014607   | 0.02         | 3.52     | 176 | Up      | 9.26E–26    |
| NONHSAT114689.2 | cis_mRNA_overlap | NM_00129858 | 0.86         | 137.81   | 160 | Up      | 3.85E–131   |
| NONHSAT056185.2 | cis_mRNA_dw20k   | NM_001127198 | 0.04         | 5.72     | 143 | Up      | 2.16E–71    |
| NONHSAT207077.1 | cis_mRNA_overlap | NM_014046   | 0.12         | 15.01    | 125 | Up      | 8.60E–17    |
| NONHSAT071221.2 | cis_mRNA_overlap | NR_130931   | 0.14         | 12.9     | 92  | Up      | 1.93E–76    |
| NONHSAT093397.2 | cis_mRNA_dw20k   | NM_0033540  | 0.01         | 0.88     | 88  | Up      | 0.0321706   |
| NONHSAT172882.1 | cis_mRNA_dw20k   | NM_013258   | 0.33         | 28.68    | 87  | Up      | 4.75E–105   |
| NONHSAT148955.1 | cis_mRNA_overlap | NM_024646   | 0.01         | 0.83     | 83  | Up      | 0.00683706  |
| NONHSAT119974.2 | cis_mRNA_overlap | NR_036501   | 0.01         | 0.74     | 74  | Up      | 2.34E–05    |
| NONHSAT138724.2 | cis_mRNA_overlap | NR_038461   | 0.09         | 6.45     | 72  | Up      | 5.57E–13    |
| NONHSAT026084.2 | cis_mRNA_dw20k   | NM_001297438 | 0.02       | 1.37     | 68.5| Up      | 0.0001099758|
| NONHSAT103660.2 | cis_mRNA_overlap | NM_001046   | 13.12       | 0.05     | 262.4| Down  | 0.001397956 |
| NONHSAT176182.1 | cis_mRNA_overlap | NM_000964   | 2.55         | 0.01     | 255 | Down  | 2.58E–08    |
| NONHSAT179933.1 | cis_mRNA_overlap | NM_001317113 | 31.62     | 0.13     | 243 | Down  | 1.94E–169   |
| NONHSAT151799.1 | cis_mRNA_overlap | NM_020624   | 4.11         | 0.02     | 205.5| Down  | 8.82E–18    |
| NONHSAT069808.2 | cis_mRNA_overlap | NM_001329113 | 4.09     | 0.17     | 204.5| Down  | 2.11E–30    |
| NONHSAT041504.2 | cis_mRNA_up10k   | NR_036650   | 6.44         | 0.04     | 161 | Down  | 0.000227306 |
| NONHSAT096955.2 | cis_mRNA_overlap | NR_015439   | 1.6          | 0.01     | 160 | Down  | 5.78E–19    |
| NONHSAT176679.1 | cis_mRNA_dw20k   | NM_001316321 | 2.82     | 0.02     | 141 | Down  | 1.04E–08    |
| NONHSAT119667.2 | cis_mRNA_overlap | NR_038367   | 1.3          | 0.01     | 130 | Down  | 9.17E–05    |
| NONHSAT097487.2 | cis_mRNA_overlap | NM_00100426 | 1.29         | 0.01     | 129 | Down  | 9.17E–05    |
| NONHSAT069824.2 | cis_mRNA_overlap | NM_005253   | 236.63       | 1.96     | 121 | Down  | 3.83E–57    |
| NONHSAT000029.2 | cis_mRNA_overlap | NR_039983   | 2.34         | 0.02     | 117 | Down  | 6.46E–37    |
| NONHSAT082319.2 | cis_mRNA_dw20k   | NM_004915   | 3.43         | 0.03     | 114 | Down  | 8.57E–27    |
| NONHSAT141480.2 | cis_mRNA_overlap | NM_00124401 | 4.46         | 0.04     | 111.5| Down  | 5.45E–42    |
| NONHSAT185717.1 | cis_mRNA_dw20k   | NR_147695   | 88           | 0.83     | 106 | Down  | 4.41E–156   |
Fig. 4 Hierarchical clustering of differentially expressed genes. a Hierarchical clustering of differentially expressed lncRNAs. b Hierarchical clustering of differentially expressed mRNAs. The color scale of the strips runs from red to blue, which means the gene was up-regulated or down-regulated. log2-fold change values were calculated from RNA-seq.
protein was observed with a loss of TANCR expression in Jurkat cells (Fig. 8f, h). Electrophoresis of RT-PCR results also confirmed the downregulation of TRAIL mRNA in the absence of TANCR (Fig. 8g). A vector with Cas9 was first transduced into primary γδ T cells (Fig. 9a). Then a guide RNA mixture (containing guide RNA 1 and guide RNA 2 used in Jurkat cells) with lentivirus was transduced into primary γδ T cells obtained from PBMCs (Fig. 9b). Our result showed that the expression of TANCR was decreased, resulting in a reduction in the expression of TRAIL mRNA and protein (Fig. 9c–e), which consistent with the results in HEK293T cell line and Jurkat cell line. In summary, these evidences demonstrate that TANCR is a noncoding RNA which positively regulates TRAIL expression in γδ T cells in responding to IPP treatment.

Discussion
Noncoding RNAs, especially lncRNA, have recently regarded as critical regulators in the immune system [26]. Developments in NGS have revealed that most DNA in the genome encodes lncRNAs [27, 28], however, the functions of lncRNAs remain to be determined. Hence, exploring the roles of lncRNA in the immune system may help us clearly understand the role that lncRNAs have. γδ T cells are well known because of their key roles in defense against various viral and bacterial infections [29–31]. IPP is an intermediate produced from mevalonate that can selectively activate and expand human γδ T cells [23, 24, 30]. NcRNA studies in the immune system are currently focused on immune cells such as natural killer (NK) cells, T helper cells, and B cells [32–35], while less is known about lncRNA regulation in γδ T cells. We therefore sought to investigate the function of lncRNAs in γδ T cell biology. In this study, γδ T cells were activated and expanded by IPP (Fig. 2). MACS was performed to purify γδ T cells. Flow cytometry was then conducted to detect the percentage of purified γδ T cells (Fig. 2). NGS and bioinformatic analysis were performed to figure out the differentially expressed mRNA and IncRNA. Go and KEGG analyses were conducted to predict the biological function and pathways of differentially expressed genes (Fig. 3). Since cis-regulation is one typical regulation mechanism in IncRNA regulation network, [13, 15] so we then predicted the potential IncRNA–mRNA pairs that are regulated in cis based on the differentially expressed genes and we summarized the top 15 upregulated and
downregulated lncRNA–mRNA pairs in Table 1. We then selected several genes that were differentially expressed in the sequencing results and performed qRT-PCR to verify the accuracy of sequencing in activated γδ T cells. qRT-PCR results showed that the RNA expression of selected genes was consistent with the sequencing
results (Fig. 5a, b), indicating that the sequencing data were valid. We focused on the regulation of lncRNA on the cytokines that are secreted by activated γδ T cells due to their important roles in γδ T cells cytotoxicity in this study. Interestingly, we found one lncRNA named TANCR (we defined the name according to a previously published paper [25]) that regulates TRAIL expression during γδ T cells activation. TANCR is a lncRNA that located downstream of the TRAIL gene (Fig. 6a). TRAIL is a cytokine that is expressed on the surface of many immune cells, including NK cells and T lymphocytes [36]. TRAIL is regarded as important antitumor cytokine because it can induce target cell apoptosis by binding to the receptors tumor necrosis factor related apoptosis-inducing ligand 1 (TRAILR1, also known as DR4) and tumor necrosis factor related apoptosis-inducing ligand 2 (TRAILR2, also known as DR5) that are expressed on the surface of target cell [37–39]. To further confirm TANCR and TRAIL expression in fresh and activated γδ T cells, we collected seven blood samples and isolated PBMCs.

**Fig. 8** Silencing of TANCR in HEK293T cells and Jurkat cells. a qRT-PCR results of TANCR expression in TANCR knockdown HEK293T cells. b qRT-PCR results of TRAIL mRNA expression in TANCR knockdown HEK293T cells. c Western blot of TRAIL protein in TANCR knockdown HEK293T cells. d Expression of Cas9 in Jurkat cells. Two vector CRISPR/Cas 9 system was used in this study, the first vector contains cas9 and GFP and the second vector contains gRNA. e qRT-PCR results of TANCR expression in TANCR knock out Jurkat cells. f qRT-PCR results of TRAIL mRNA expression in TANCR knock out Jurkat cells. g Agarose gel electrophoresis of qRT-PCR results. h Western blot of TRAIL protein in TANCR knock out Jurkat cells. qRT-PCR and western blot were normalized by GAPDH. Graphs show the mean values ± SEM and data obtained from three independent experiments. p value is calculated by Student’s t-test.
samples respectively. After IPP treatment for two weeks, RT-PCR was performed and the results revealed that the expression of TANCR and TRAIL were both upregulated in IPP-expanded γδ T cells from seven samples (Fig. 5c, d). In addition, Spearman analysis showed a correlation between TANCR and TRAIL (Fig. 5e). These results indicate that TANCR might regulate TRAIL expression during the activation of γδ T cells. We also found that TANCR expression was much higher in γδ T cells than in L-02 cell line, Jurkat cell line, K562 cell line, A549 cell line, and HEK293T cell line (Fig. 5f), which emphasizes the potential function of TANCR in γδ T cells. We then isolated nuclear and cytoplasmic RNA from HEK293T cells and Jurkat cells and found that TANCR localized both in nucleus and cytoplasm (Fig. 6b, c).

An TANCR overexpression vector was constructed and transfected into HEK293T cells, we found both of the TRAIL mRNA and protein were increased (Fig. 7). TANCR was located both in the nucleus and cytoplasm, while it was much more highly expressed in the cytoplasm than in the nucleus (Fig. 6b, c). Therefore, A mixture of siRNA and ASO reduced the expression of TRAIL both at the mRNA and protein level (Fig. 8b, c). To further confirm the regulation between TANCR and TRAIL, we used CRISPR/Cas9 system to knock out TANCR in Jurkat cells and primary γδ T cells. A plasmid containing the cas9 protein was first transduced into cells using a lentivirus followed by guide RNAs. With the silencing of TANCR, TRAIL mRNA and protein were both decreased in Jurkat cells and primary γδ T cells (Figs. 8f, h, 9c, e), consistent with the results from HEK293T cell line. Hence, these evidences demonstrate that we identified a lncRNA named TANCR that is predominantly expressed in the cytoplasm and positively regulates TRAIL expression in cis in activated γδ T cells. In addition, our data revealed that the lncRNA and mRNA expression in IPP-expanded γδ T cells is significantly different from fresh γδ T cells controls. We also predicted the potential effect of these differentially expressed genes and the interaction between lncRNA and mRNA that can be used for further studies.

In this study, we found TANCR is highly expressed in activated γδ T cells, which means that TANCR is important in regulating γδ T cells activation by promoting TRAIL expression. The upregulation of
TANCR and TRAIL in IPP-activated γδ T cells from seven samples indicates that TANCR might also be a potential activation marker for γδ T cells. However, this hypothesis should be confirmed by testing a larger number of samples. The regulation between TRAIL and TANCR in NK cells should be validated due to TRAIL is also considered as a NK cell cytokine [40, 41]. The current study focused on regulation occurring in cis, while IncRNAs can also regulate gene expression in trans or directly interact with proteins [13]. These interactions should be considered as important mechanisms during IncRNA regulation that can be studied in the immune response. γδ T cells are distributed in many lymphoid tissues [42], and the discovery of tissue-specific IncRNAs may be important to better understanding γδ T cells biology. Meanwhile, there are various cytokines that are expressed by γδ T cells, and the functions of IncRNAs in regulating other cytokines should also be identified. However, γδ T cells make up a small part of the immune system, and there are numerous immune cells during the immune response. It is therefore necessary to identify the function of IncRNAs in other immune cells, which will help us construct a precise IncRNA regulation network in the immune system.

Conclusion
In summary, we have provided evidence that the lncRNA TANCR, expressed predominantly in the cytoplasm, positively regulates TRAIL expression in γδ T cell, which demonstrate an enhanced function of IncRNAs in γδ T cell activation.

Material and methods

Study subject
All the samples used in this study were obtained from West China Second University Hospital with informed consent from all participants, following the Ethics Committee of Sichuan University.

Cell isolation and γδ T cells preparation
Ficoll (TBD, Tianjin, China) was used to isolate PBMCs. Ficoll was pipetted into a 50 ml tube, and the blood was added to the tube gently. Centrifuge the 50 ml tube for 20 min at 800g. Pipette the cell layer (PBMCs) between blood and Ficoll into a clean 50 ml tube. Cold phosphate buffer saline (PBS) was used to wash the cells twice and the cells were centrifuged at 600g for 5 min. The isolated PBMCs were exposed to IPP (6 μg/ml) added medium for 3 days and then cultured in medium containing IL-2 (Invitrogen, Carlsbad, CA, USA) up to two weeks. Fresh medium was added every 3 days [43]. γδ T cells were finally purified with an Anti-TCR gamma delta Micro-Bead Kit (Miltenyi Biotec, Germany) from IPP treated PBMCs according to the manufacturer’s instructions.

Cell culture and viral infection
DMEM medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, Carlsbad, CA, USA) was used to culture HEK293T cells. Jurkat cells and primary γδ T cells were cultured in RPMI medium (Invitrogen, Carlsbad, CA, USA) with 10% FBS. All the medium was supplemented with 100 μg/ml streptomycin and 100 U/ml penicillin (Gibco). Cells were cultured at 37 °C in a 5% CO2 incubator (Sanyo, Osaka, Japan). siRNAs were used to silencing TANCR expression in HEK293T cells. A negative control siRNA (NC siRNA) was used. siRNA/ASO was transfected using Lipofectamine™ RNAi MAX Transfection Reagent (Invitrogen, Cartsbad, USA). To knock out TANCR in Jurkat cells and γδ T cells, a vector containing TANCR guide RNAs and plasmid containing cas9 protein were packaged in HEK293T cells respectively. Jurkat cells and γδ T cells were firstly infected with cas9 lentivirus and selected by G418. TANCR guide RNA lentivirus was then transduced in these cells [44].

RNA-Seq
RNA was extracted from IPP-expanded and fresh γδ T cells using Trizol (Invitrogen, Cartsbad, USA), followed by ribosomal RNA removal using Ribo-Zero™ rRNA Removal Kit (Epigentre, Madison, WI, USA). A strand specific cDNA library was constructed using TruSeq® Stranded kit (Illumina, Madison, WI, USA). RNA sequencing was conducted by an Illumina Hi Seq 4000 platform (Illumina, San Diego, CA, USA) by Novogene. The sequenced reads were aligned to the human reference genome with HISAT [45] and PossionDis [46] was used to select differential expressed IncRNA/mRNA (fold change <−2 or >2 and FDR p value <0.05).

Flow cytometry
Cells were blocked with 5% BSA diluted in PBS for 20 min and then stained with the following surface antibodies: anti-CD3, anti-TCR γδ, and anti-TRAIL for 30 min. Cold PBS was then used to wash the cells three times. Flow cytometry (BD FACSCelesta) was used to detect the cells, and FlowJo software was used to analyze the data. Antibodies used were obtained from Biolegend (San Diego, USA). Antibodies were obtained from BD.

Nuclear and cytoplasmic RNA isolation
The nuclear and cytoplasmic RNA was isolated using protocol from Cold Harbor Laboratory [47]. Briefly,
HEK293T cells and Jurkat cells were collected from tissue culture dishes and washed by cold phosphate-buffered saline (PBS) for three times. Then the cells were resuspended in cold disruption buffer (1.5 mM MgCl₂, 10 mM KCl, 20 mM Tris–HCl, pH = 7.5, 1 mM DTT). Cells were then incubated on ice for 10 min. Dounce homogenizer was used to disrupt the cell membrane. The microscope was used to ensure that 90% of the cell membrane was broken during homogenate. The nuclei should not be broken. The homogenate was then transferred to a fresh tube and Triton X-100 was added to make a final concentration of 0.1%. The tubes were inverted four to five times. The nuclear and cytoplasmic fractions were separated by centrifuging the homogenate at 1500g for 5 min. The supernatant was transferred to a fresh tube without disturbing the nuclear pellet. RNA was extracted using Trizol according to the manufacturer’s instruction (Invitrogen, Carlsbad, USA).

RNA extraction and qRT-PCR
Trizol was used to extract RNA. Reverse transcription was conducted with SuperScript™ III First-Strand Synthesis System (Invitrogen, Carlsbad, USA) according to the manufacturer’s instructions. PowerUp™ SYBR™ Green Master Mix was used to perform qRT-PCR on an Applied Biosystems 7500 (Life technologies, Carlsbad, USA). The qRT-PCR results were normalized by internal control GAPDH. Sequence of primers is shown in Table 2. Primers were synthesized by GENEWIZ (Suzhou, China).

Western blot
Cells were harvested using lysis buffer (Beyotime). Proteins were separated by a 12% SDS-PAGE gel and then transferred to a nylon membrane. 5% skim milk diluted in PBS-T (1% of Tween-20 in PBS) was used to block the membrane at room temperature for 1 h. Primary antibody diluted with PBS-T was incubated with the membrane at 4 °C overnight (TRAIL, ProteinTech) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Abcam) antibody with a dilution of 1:1000. After the membrane was washed with PBS-T three times for 5 min, the membrane was then incubated with horseradish peroxidase-conjugated secondary antibody (CST) diluted with PBS-T for 1 h at room temperature. Pierce™ ECL Western Blotting Substrate (Thermo, Carlsbad, USA) was used to detect the signal by using a Chemidoc imaging system (Bio-Rad Laboratories) [48].

Abbreviations
lncRNA: Long noncoding RNA; PBMCs: Peripheral blood mononuclear cells; TCR: T cell receptor; TRAIL: Tumor necrosis factor related apoptosis-inducing ligand; TANCR: Tumor necrosis factor related apoptosis-inducing ligand activated noncoding RNA.; IPP: Isopentenyl pyrophosphate.; Fas: Factor associated suicide; Fasl: Factor associated suicide ligand; IFN-γ: Interferon-γ; APCs: Antigen presenting cells; IL-10: Interleukin 10; TGF-β: Transforming growth factor β.

Authors’ contributions
CY, HL designed the research. CY wrote the manuscript and performed most of the experiment. TF, FL, and TXG provided the PBMCs. SY and YHT analyzed the sequencing results. HL edited the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (No. 81671497) and Key research and development projects of Science and Technology Department of Sichuan Province (2017SZ0112).

Available of data and materials
The data that support the findings of this study are available from the corresponding author upon request.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University, No. 17, South Renmin Rd, Chengdu 610000, China. 2 Chengdu Blood Center, No. 3, East Yujie Rd, Chengdu 610000, China. 3 Department of Pediatrics, West China Second University Hospital, Sichuan University, No. 20, South Renmin Rd, Chengdu 610000, China.

Received: 12 November 2019   Accepted: 3 February 2020
Published online: 12 February 2020

References
1. Hayday AC. γδ T cell update: adaptate orchestrators of immune surveillance. J Immunol. 2019;203:311–20.
2. Cavalcanti De Albuquerque R, Granato A, Silva Castro I, Carvalho Torres R, Santos Souza F, Lima MA, et al. Phenotypic and functional changes

Table 2  Real time-PCR primers

| Name        | Sequence                |
|-------------|-------------------------|
| GAPDH-forward | GAGTCACCGGATTTGCGCGT    |
| GAPDH-reverse | TTGATTTTGGAGGGACTCG     |
| TRAIL-forward | CAAGCCCATCAAGGACTGG     |
| TRAIL-reverse | GAAGTGAGCGGAGGGATT      |
| TANCR-forward | TCTGGCTCTCAAATGTGACT    |
| TANCR-reverse | TCAACCTTCGCAAGTGCTT     |
| U6-forward   | CTGCCCTCGGACAGCATAATCT  |
| U6-reverse   | ACCATGGCACTAGTGGTGCTC   |
| Cas9-forward | CATCGACGACATGACGAGGT    |
| Cas9-reverse | CGATCCTGGTCCTGACAGG     |
in gamma delta T lymphocytes from HTLV-I carriers. J Leukoc Biol. 2019;106:607–18.

3. Born WK, Reardon CL, O’Brien RL. The function of γδ T cells in innate immunity. Curr Opin Immunol. 2008;18:31–8.

4. Hong C, Zeng Y, Tu W. The role of γδ T cells during human pregnancy. Am J Reprod Immunol. 2017;78:1–5.

5. Kobayashi H, Tanaka Y. γδ T cell immunotherapy—a review. Pharmaceuticals. 2015;8:40–61.

6. Duaull C, Franchini DM, Familliades J, Cayrol C, Roga S, Girard J-P, et al. TCRVγ9 γδ T cell response to IL-33: a CD4 T cell-dependent mechanism. J Immunol. 2016;196:493–502.

7. Puan KJ, Jin C, Wang H, Sarikonda G, Raker AM, Lee HK, et al. Preferential activation of infected langerhans cells and impedes migration of infected langerhans cells by inducing apoptosis and blocking E-cadherin downregulation. J Immunol. 2010;185:477–87.

8. Cua DJ. Innate IL-17-producing cells: the sentinels of the innate immune system. Nat Rev Immunol. 2010;10:479–89.

9. Agrati C, Cimini E, Sacchi A, Bordoni V, Gioia C, Casetti R, et al. Activated Vγ9Vδ2 T cells trigger granulocyte functions via MCP-2 release. J Immunol. 2009;182:522–9.

10. Moser B, Eberli M, Y-TPAPC: A novel tool for immunotherapy? Cell Mol Life Sci. 2011;68:2443–52.

11. Exley MA, Boyson JE. Protective role of regulatory decidual γδ T cells in pregnancy. Clin Immunol. 2011;141:236–9.

12. Murphy K, Weaver C. Janeway’s immuno biology. 9th ed. New York: Garland Science; 2017.

13. Yang C, Shen C, Feng T, Li H. Noncoding RNA in NK cells. J Leukoc Biol. 2019;105:65–71.

14. Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing. A look under the hood of miRISC. Nat Struct Mol Biol. 2012;19:586–93.

15. Guttmann R, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012;482:339–46.

16. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. A short guide to long non-coding RNA gene nomenclature. Nat Rev Immunol. 2015;15:683–91.

17. Wang H, Henry O, Distefano MD, Wang Y-C, Raikkonen J, Monkkonen J, et al. Butyrophilin 3A1 plays an essential role in pentyli pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol. 2013;191:1029–42.

18. Bonville M, O’Brien RL, Born WK. γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010;10:467–78.

19. Peschansky VJ, Wahlestedt C. Non-coding RNAs as direct and indirect modulators of epigenetic regulation. Epigenetics. 2014;9:3–12.

20. Bezman NA, Cedars E, Steiner DF, Bliekel R, Hesslein DGT, Lanier LL. Distinct requirements of MicroRNAs in NK cell activation, survival, and function. J Immunol. 2010;185:3835–46.

21. Atianand MK, Fitzgerald KA. An RNA twist to TH17 cells. Science (80-). 2016;351:1032.

22. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008;8:782–98.

23. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Nature Rev Cancer. 2008;8:658–69.

24. Koutoulaki M, Cimino E, Samy S, Usauge J-P, et al. A long noncoding RNA lincRNA-EPS acts as a transcriptional brake to restrain inflammation. Cell. 2016;165:1672–85.

25. Yang M, Liu L, Xie M, Sun X, Yu Y, Kang R, et al. Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy. Autophagy. 2015;11:214–24.

26. Atianand MK, Fitzgerald KA. An RNA twist to TH17 cells. Science (80-). 2016;351:1032.

27. Djebari S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature. 2012;489:101–8.

28. Chen YG, Satpathy AT, Chang HY. Gene regulation in the immune system by long noncoding RNAs. Nat Immunol. 2017;18:962–72.

29. Silva-Santos B, Seure K, Novell H. γδ T cells in cancer. Nat Rev Immunol. 2015;15:683–91.

30. Wang H, Henry O, Distefano MD, Wang Y-C, Raikkonen J, Monkkonen J, et al. Butyrophilin 3A1 plays an essential role in pentyli pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol. 2013;191:1029–42.

31. Nonvolle M, O’brien RL, Born WK. γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010;10:467–78.

32. Bezman NA, Cedars E, Steiner DF, Bliekel R, Hesslein DGT, Lanier LL. Distinct requirements of MicroRNAs in NK cell activation, survival, and function. J Immunol. 2010;185:3835–46.

33. Bzdak TF, Johnson JS, Muller J, Heger A, Ponting CP, Tybulewicz VJL. Long noncoding RNAs in B-cell development and activation. Blood. 2016;128:e10–e199.

34. Atianand MK, Fitzgerald KA. An RNA twist to TH17 cells. Science (80-). 2016;351:1032.

35. Peng H, Liu Y, Tian J, Ma J, Tang X, Rui K, et al. The long noncoding RNA IFNG-AS1 promotes t helper type 1 cells response in patients with Hashimoto’s thyroiditis. Sci Rep. 2015;5:17702.

36. Yang M, Liu L, Xie M, Sun X, Yu Y, Kang R, et al. Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy. Autophagy. 2015;11:214–24.

37. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008;8:782–98.

38. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Nature Rev Cancer. 2008;8:658–69.

39. Wajant H. Molecular mode of action of TRAIL receptor agonists—Common principles and their translational exploitation. Cancers (Basel). 2019;11:954.

40. Caligiuri MA. Human natural killer cells. Blood. 2008;112:461–9.

41. Li T, Yang Y, Song H, Li H, Cui A, Liu Y, et al. Activated NK cells kill hepatic stellate cells via p38/P3K signaling in a TRAIL-involved degradation manner. J Leukoc Biol. 2019;105:695–704.

42. Paget C, Trotein F. Mechanisms of bacterial superinfection post-infection: a role for unconventional T cells. Front Immunol. 2019;10:336.

43. Liu X, Feng T, Gong T, Shen C, Zhu T, Wu Q, et al. Human umbilical cord mesenchymal stem cells inhibit the function of allogeneic activated Vγ9Vδ2 T lymphocytes in vitro. BioMed Res Int. 2015;2015:317801.

44. Sheng C, Quan Q, Yang C, Wen Y, Li H. Histone demethylase JMJD6 regulates cellular migration and proliferation in adipose-derived mesenchymal stem cells. Stem Cell Res Ther. 2018;9:1–13.

45. Kim D, Langmead B, Salzberg SL. HISAT: A fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357–60.

46. Audic S, Claverie JM. The significance of digital gene expression profiles. Genome Res. 1997;7:986–95.

47. Yang et al. Cell Biosci (2020) 10:15

Publisher’s Note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.